Veracyte (VCYT) Q1 2026: Decipher Volumes Up 24% as Major Launches Set Stage for Next Growth Cycle
Veracyte’s core franchises delivered robust growth and margin expansion in Q1, as Decipher volumes rose 24% and Afirma benefited from operational upgrades. With Prosigna LDT and TruMRD launches imminent, the company is poised to enter new high-value cancer testing markets, while management raises guidance and signals sustained double-digit growth through 2026.
Summary
- Decipher Momentum Accelerates: Prostate cancer test volumes surged, reinforcing the franchise as Veracyte’s primary growth engine.
- Operational Leverage Expands: Margin gains and improved test delivery reflect scalable infrastructure and disciplined investment.
- Product Launches Drive Inflection: Prosigna LDT and TruMRD launches are set to expand the company’s addressable market and evidence base.
Business Overview
Veracyte is a molecular diagnostics company focused on oncology, generating revenue by providing advanced genomic tests that inform cancer care decisions. Its major segments include Decipher, prostate and bladder cancer gene expression testing, and Afirma, thyroid nodule risk assessment, with new platforms like Prosigna LDT, breast cancer stratification, and TruMRD, minimal residual disease detection, set to expand its clinical footprint. The business model centers on test volume, reimbursement, and clinical adoption, with real-world evidence and clinical guidelines driving payer coverage and physician uptake.
Performance Analysis
Veracyte delivered a strong start to 2026, with total revenue up 21% year-over-year and testing revenue climbing 26%, driven by Decipher’s 24% volume growth and Afirma’s 12% increase. Decipher’s momentum was fueled by broadening adoption in both advanced and low-risk prostate cancer, with nearly 30% growth in high-risk test categories. Afirma’s operational turnaround, enabled by the full transition to the V2 transcriptome workflow, reduced no-result rates and contributed an incremental 400 basis points to volume growth.
Gross margin expanded to 75.7%, up 350 basis points, reflecting operational efficiencies and a favorable business mix. The company’s adjusted EBITDA margin hit 30.8%, well above its long-term target, underscoring the scalability of its core franchises. Management highlighted that the improvement in no-result rates for Afirma is sustainable, but expects some seasonal moderation in future quarters. Notably, guidance was raised for both revenue and adjusted EBITDA, reflecting confidence in continued execution and the impact of operational upgrades.
- Decipher Penetration Remains Early: With only one in three eligible U.S. prostate cancer patients tested, the franchise retains significant runway for multi-year growth.
- Afirma Platform Upgrades Yield Tangible Gains: The V2 transcriptome workflow improved delivery rates and reduced costs, supporting both patient outcomes and profitability.
- Cash Generation Supports Flexibility: Operating cash flow reached $35.2 million, with a $439 million cash position enabling future investment and M&A optionality.
Veracyte’s performance reflects a blend of core test adoption, operational discipline, and a pipeline that is now transitioning from R&D to commercial launch mode.
Executive Commentary
"This quarter highlights years of disciplined execution that have transformed VeriSight into a stronger, more focused, scalable company... We’re on the cusp of our two most significant product launches since Afirma. First, Prosigna LDT... and second, TruMRD, launching initially in muscle-invasive bladder cancer. Together, these launches will expand our addressable market, extend our platform into new clinical settings, and position us for what we expect will be an even more transformative next five years for Verisight and the industry."
Mark Stapley, Chief Executive Officer
"Adjusted EBITDA was 42.8 million, or 30.8% of revenue, up 73% year-over-year, and well above our long-term target of 25%. This level of profitability underscores the operating leverage we've built over the last five years and provides the flexibility to continue investing in our growth drivers while generating meaningful cash."
Rebecca Chambers, Chief Financial Officer
Strategic Positioning
1. Decipher’s Evidence-Driven Expansion
Decipher continues to build competitive advantage via robust clinical evidence and guideline inclusion, now covering the full prostate cancer risk spectrum and expanding into bladder cancer. Ongoing phase 3 trials and real-world data reinforce its utility, with upcoming ASCO presentations expected to further validate the platform and drive adoption among urologists and oncologists.
2. Afirma’s Platform Evolution
The transition to the V2 transcriptome workflow has structurally improved Afirma’s cost and delivery profile, enabling more definitive results for challenging samples. This not only boosts volume and margin but also enhances physician and patient trust, supporting durable growth as the leading test for indeterminate thyroid nodules.
3. Product Pipeline Poised for Inflection
Prosigna LDT and TruMRD represent Veracyte’s most significant launches in years, targeting large, underserved markets in breast cancer risk stratification and minimal residual disease detection. Both launches are supported by major clinical trials (Optima for Prosigna, multiple studies for TruMRD), with management emphasizing evidence-based differentiation and commercial readiness.
4. Operational Leverage and Capital Allocation
Margin expansion and strong cash generation provide Veracyte with strategic flexibility, enabling continued R&D investment, commercial build-out for new launches, and the option for selective M&A. Management remains disciplined, focusing on oncology and data-driven assets that fit Veracyte’s platform strategy.
5. Competitive Moat Built on Evidence and Scale
While digital pathology and AI-based entrants are emerging, Veracyte’s decade-long evidence base, high-volume database, and deep clinical integration create barriers to entry. Leadership views price competition as secondary to clinical validation and utility, with ongoing investment in digital and AI initiatives to further strengthen the moat.
Key Considerations
This quarter’s results reflect a business entering a new phase, with core franchises delivering predictable growth and two major launches set to expand the company’s reach and relevance in oncology diagnostics. Investors should weigh the following:
Key Considerations:
- Decipher’s Penetration Opportunity: Only a third of eligible prostate cancer patients currently benefit from Decipher, leaving substantial room for multi-year volume growth as evidence and coverage expand.
- Afirma’s Operational Improvements Are Durable: Workflow upgrades are expected to sustain lower no-result rates, though seasonal factors may introduce quarterly variability.
- Upcoming Launches Could Redefine Growth Trajectory: Prosigna LDT and TruMRD launches are not yet included in guidance, offering potential upside if clinical and commercial milestones are met.
- Margin Structure Supports Investment: Elevated profitability provides a cushion to absorb launch investments and R&D, while maintaining cash flow and optionality.
- Competitive Landscape Shifting: While new digital and AI diagnostics are emerging, Veracyte’s evidence base and provider relationships remain a key differentiator.
Risks
Key risks include execution around new product launches, particularly the ability to drive adoption and reimbursement for Prosigna LDT and TruMRD in competitive or underpenetrated markets. Regulatory and guideline timing could delay uptake, while emerging digital competitors and potential pricing pressure may challenge long-term margin structure. Quarterly variability in prior period collections and operational factors (such as weather or sample quality) could impact near-term results.
Forward Outlook
For Q2 2026, Veracyte guided to:
- Continued double-digit revenue and test volume growth in core franchises
- Operational margin expansion, with adjusted EBITDA expected above 26% for the full year
For full-year 2026, management raised guidance:
- Total revenue of $582 million to $592 million, up from $570 million to $582 million previously
- Testing revenue growth of 16% to 18%, with Decipher at ~20% and Afirma in the high single to low double digits
Management highlighted that guidance excludes contributions from new product launches and prior period collections, and that continued investment in commercial and R&D capabilities is expected as launches ramp.
- Prosigna LDT and TruMRD launches expected to begin by mid-year and end of Q2, respectively
- Ongoing evidence generation and trial readouts to drive future guideline inclusion and coverage
Takeaways
Veracyte’s Q1 results reinforce the durability and scalability of its core franchises, while the pipeline is positioned to unlock new addressable markets and accelerate growth. Margin expansion and cash generation provide strategic flexibility, but execution on near-term launches and evidence generation will be critical for sustaining momentum.
- Core Franchise Strength: Decipher and Afirma continue to outperform, with operational upgrades translating into both volume and margin gains.
- Pipeline Execution Is the Next Catalyst: Success in Prosigna LDT and TruMRD launches could materially expand Veracyte’s growth profile and market relevance.
- Watch for Evidence Readouts and Commercial Uptake: Investors should track Optima and other trial outcomes, as well as early adoption metrics for new launches, as leading indicators for sustained outperformance.
Conclusion
Veracyte enters the next phase of its evolution with strong core momentum, expanding operational leverage, and high-impact launches on the horizon. Execution on clinical, commercial, and operational fronts will determine whether the company can translate its pipeline into durable, multi-year growth.
Industry Read-Through
Veracyte’s results signal that evidence-backed molecular diagnostics remain the gold standard in oncology, with real-world data and clinical guideline inclusion driving adoption and payer coverage. The operational improvements in test delivery and margin structure highlight the value of scalable infrastructure in diagnostics, especially as new entrants leverage digital and AI tools. Upcoming launches in breast cancer and MRD signal a shift toward multi-cancer, platform-based approaches, suggesting that future industry winners will be those who can combine deep evidence, clinical integration, and operational excellence. For peers and new entrants, the bar for clinical validation, provider trust, and reimbursement remains high, reinforcing the importance of long-term evidence generation and commercial discipline.